AX-2025-019096

Epitalon · 10 mg declared · Guangzhou JEEP Biotechnology Co., Ltd. · lot JEEP-2502-J3559

FAILMETHOD LIMITED

Report ID: AX-2025-019096
Compound: Epitalon
Compound class: Short bioregulator peptides
Supplier: JEEP — Guangzhou JEEP Biotechnology Co., Ltd.
Batch / lot: JEEP-2502-J3559
Declared label claim: 10mg
Laboratory: PeptideMeter
Assay date: 04 Jun 2025
Submitted: 09 Jun 2025
Quarter: 2025-Q2
Submitter: fill_homogeneity
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the short bioregulator peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 28 min gradient, 214 nm	99.93	% area	≥ 99.0	PASS
Total impurities	RP-HPLC, sum of reported peaks	0.07	% area	≤ 1.0	PASS
Largest single impurity	RP-HPLC — Ala-Glu-Asp tripeptide (−57 Da)	0.04	% area	≤ 1.00	PASS
Identity	not ordered on this submission	not determined	—	required for VERIFIED status	NOT TESTED
Total peptide content	by difference from the gravimetric mass balance	77.71	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	77.66	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	13.51	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	10.492	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	104.9	%	90.0 – 110.0	PASS
Water content	Karl Fischer, coulometric, duplicate	8.85	%	≤ 12.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	13.15	%	≤ 10.0	FAIL
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.29	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Visible particulates, did not clear	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.90	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 28 min gradient	4.25	min	4.34 ± 0.20 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.09	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	80,208	—	≥ 20,000	PASS
Resolution to nearest impurity	vs β-Asp isomer	1.52	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 28 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 80,208, and skew follows the reported asymmetry factor of 1.09. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.04 % impurity against a 99.93 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	Epitalon — main peak	4.25	4,856,908	99.93	—
2	Ala-Glu-Asp tripeptide (−57 Da)	4.06	1,944	0.04	-57.021
3	β-Asp isomer	4.16	1,458	0.03	0.000
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	8.85
Counter-ion (acetate)	ion chromatography	13.15
Residual solvent + inorganic residue	estimated	0.29
Total peptide content	by difference	77.71
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	99.90	99.93	divergence -0.03 pp vs batch median
Total impurities (% area)	0.10	0.07
Largest single impurity (% area)	0.05	0.04
Water (%)	8.4	8.85
Counter-ion (%)	not stated	13.15
Peptide content (%w/w)	not stated	77.71
Endotoxin (EU/mg)	1.49	not determined
Method stated on certificate	YES	—	column, gradient and wavelength given

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 4 d) → assay. Submitter did not handle the vial.
Assay date: 04 Jun 2025
Submitted to the index: 09 Jun 2025
Laboratory: PeptideMeter, Tallinn, Estonia
Method basis: 28 min gradient · high-resolution MS
Verification status: METHOD LIMITED

What this report does not establish

That the compound is the compound named. No identity confirmation was ordered on this submission. A purity figure describes chromatographic homogeneity of whatever eluted; it does not name it.
That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot JEEP-2502-J3559 n=2

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2025-019095	JEEP-2502-J3559	Janoshik	2025-Q2	99.93	9.67	94.1	Supplier-supplied	0	FAIL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent Epitalon records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043099	KP	KP-2512-R5829	PeptideMeter	2026-Q2	98.33	6.52	94.5	Supplier-supplied	2	FAIL
AX-2026-042209	Homopeptide	HOMO-2512-A1223	Janoshik	2026-Q2	99.93	7.83	100.3	Supplier-supplied	0	FAIL
AX-2026-042208	Homopeptide	HOMO-2512-A1223	PeptideMeter	2026-Q2	99.36	7.93	102.7	Supplier-supplied	0	FAIL
AX-2026-043098	KP	KP-2512-R5829	Janoshik	2026-Q2	97.71	6.99	—	Supplier-supplied	2	FAIL
AX-2026-041270	WWB	WWB-2602-G2822	Janoshik	2026-Q2	99.75	6.69	88.9	Supplier-supplied	1	MARGINAL
AX-2026-043097	KP	KP-2512-R5829	Janoshik	2026-Q2	98.00	6.74	91.6	Supplier-supplied	2	FAIL
AX-2026-043096	KP	KP-2512-R5829	Medutest	2026-Q2	97.61	6.38	97.0	Buyer-sourced	3	FAIL
AX-2026-043095	KP	KP-2512-R5829	Janoshik	2026-Q2	97.68	6.82	—	Supplier-supplied	2	FAIL

Other recent JEEP records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041847	TB-500	JEEP-2602-V3434	Nordanalyt	2026-Q3	99.72	3.85	—	Supplier-supplied	1	MARGINAL
AX-2026-041886	Semaglutide	JEEP-2607-X3911	Nordanalyt	2026-Q3	99.19	4.03	96.4	Supplier-supplied	2	MARGINAL
AX-2026-041882	Semaglutide	JEEP-2607-X3911	Nordanalyt	2026-Q3	99.17	4.52	—	Supplier-supplied	1	MARGINAL
AX-2026-041845	TB-500	JEEP-2602-V3434	Janoshik	2026-Q3	99.72	4.04	102.2	Supplier-supplied	1	MARGINAL
AX-2026-041921	TB-500	JEEP-2605-M4874	Janoshik	2026-Q3	99.90	1.76	—	Supplier-supplied	2	MARGINAL
AX-2026-041922	TB-500	JEEP-2605-M4874	Janoshik	2026-Q3	99.41	2.60	95.7	Laboratory-retained	2	MARGINAL
AX-2026-041928	TB-500	JEEP-2605-M4874	Janoshik	2026-Q3	99.88	1.84	92.8	Laboratory-retained	2	MARGINAL
AX-2026-041849	TB-500	JEEP-2602-V3434	VendorInvestigate	2026-Q3	99.73	3.60	88.6	Buyer-sourced	2	MARGINAL